Gaithersburg’s Sirnaomics Secures $105 Million in Series E Financing to Fund Development of Novel RNAi Therapeutics

Published on :

Proceeds to Fund Development of Novel RNAi Therapeutics for Cancers, Viral Infections, Fibrosis, and Metabolic Diseases